ArticleCancer communications (London, England)2025

PTPN9 regulates HER3 phosphorylation during trastuzumab treatment and loss of PTPN9 is a potential biomarker for trastuzumab resistance in HER2 positive breast cancer.

Abul Azad et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.